Valeria Denninghoff

Ministry of Health and Social Welfare, Spain

Title: Innovative Public Procurement in Liquid Biopsy: A public initiative to implement new technologies in the clinical practice in the Andalusian Health System.

---

Biography

Dr. Denninghoff founded in 1999 and directed for more than 20 years the first Molecular Pathology laboratory in Argentina, Specialist in Clinical Precision Medicine in breast, colon, lung, and pancreatic cancer, from a deep approach to NGS techniques for ctDNA and prenotification/genotification of CTC. He has consubstantiated his training with Drs. Wistuba at MD Anderson in Texas, Soares at the AC-Camargo in Sao Paulo, and Liderau at the Rene Huguenin Center in Paris. He is currently working on Liquid Biopsy with Drs. Rolfo of Mount Sinai in New York, and Serrano of GENYO Spain.

Abstract

Traditional Public Procurement is in the process of changing towards a new scenario. The Innovative Public Procurement (IPP) offers the Andalusian Public Health System (APHS) a new approach to acquiring new solutions. Then, "PRECISION DIAGNOSIS AND TREATMENT IN INFECTIOUS DISEASES AND CANCER" was a project co-financed 80% by the European Regional Development Fund and whose main objective is the development of innovative solutions in the APHS. The project's main objectives are obtaining innovative platforms that allow identifying and characterizing biomarkers in the blood (CTCs and ctDNA) to monitor the patient in real-time, predict potential relapses early, and track the response to treatment of a custom shape. 

Material and method. The device must analyze a minimum of ten genes with five mutations each, including RAS family, EGFR, HER2, and PI3K, and distinguish between high and low mutation frequencies. The detection of allelic frequencies must be in a range of 0.1 to 0.5.

Results and Discussion. Two prototypes of new technologies were performed to identify and characterize biomarkers in the blood (CTCs, exosomes, and free DNA) in an automated and simultaneous way for early diagnosis, personalization, and monitoring of cancer patients. The validation process is ongoing and includes the analysis of a representative sample of patients with breast, colon, and lung carcinoma (15 patients/tumor/stage).

Conclusion. The IPP acted as an instrument to promote the commercial market. The Liquid Biopsy project developed two prototypes that allow the identification and characterization of blood biomarkers to personalize and monitor patient treatment